|
1) Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1969; 32: 28-34
|
|
|
|
2) Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci. 1989; 94: 79-100
|
|
|
|
|
|
3) Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999; 163: 94-8
|
|
|
|
|
|
4) Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002; 125: 1070-83
|
|
|
|
|
|
5) Geser F, Wenning GK, Seppi K, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord. 2006; 21: 179-86
|
|
|
|
|
|
6) May S, Gilman S, Sowell BB, et al. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007; 22: 2371-7
|
|
|
|
|
|
7) Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004; 19: 1391-402
|
|
|
|
|
|
8) Hara K, Momose Y, Tokiguchi S, et al. Multiplex families with multiple system atrophy. Arch Neurol. 2007; 64: 545-51
|
|
|
|
|
|
9) Soma H, Yabe I, Takei A, et al. Heredity in multiple system atrophy. J Neurol Sci. 2006; 240: 107-10
|
|
|
|
|
|
10) Wullner U, Abele M, Schmitz-Huebsch T, et al. Probable multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry. 2004; 75: 924-5
|
|
|
|
|
|
11) Wullner U, Schmitt I, Kammal M, et al. Definite multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry. 2009; 80: 449-50
|
|
|
|
|
|
12) Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71: 670-6
|
|
|
|
|
|
13) Dodel R, Spottke A, Gerhard A, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010; 25: 97-107
|
|
|
|
|
|
14) Osaki Y, Ben-Shlomo Y, Lees AJ, et al. A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord. 2009; 24: 2272-6
|
|
|
|
|
|
15) Brooks DJ, Seppi K, Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord. 2009; 24: 949-64
|
|
|
|
|
|
16) Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology. 2002; 58: 575-80
|
|
|
|
|
|
17) Schocke MF, Seppi K, Esterhammer R, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinsonʼs disease. Neuroimage. 2004; 21: 1443-51
|
|
|
|
|
|
18) Seppi K, Schocke MF, Prennschuetz-Schuetzenau K, et al. Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord. 2006; 21: 847-52
|
|
|
|
|
|
19) Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinsonʼs disease and progressive supranuclear palsy. Brain. 2006; 129: 2679-87
|
|
|
|
|
|
20) Okawa M, Miwa H, Kajimoto Y, et al. Transcranial sonography of the substantia nigra in Japanese patients with Parkinsonʼs disease or atypical parkinsonism: clinical potential and limitations. Intern Med. 2007; 46: 1527-31
|
|
|
|
|
21) Walter U, Dressler D, Probst T, et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol. 2007; 64: 1635-40
|
|
|
|
|
|
22) Walter U, Niehaus L, Probst T, et al. Brain par-enchyma sonography discriminates Parkinsonʼs disease and atypical parkinsonian syndromes. Neurology. 2003; 60: 74-7
|
|
|
|
|
|
23) Ito M, Watanabe H, Kawai Y, et al. Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2007; 78: 722-8
|
|
|
|
|
|
24) Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010; 9: 149-58
|
|
|
|
|
|
25) Gerhard A, Banati RB, Goerres GB, et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. 2003; 61: 686-9
|
|
|
|
|
|
26) Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinsonʼs disease. Neurobiol Dis. 2006; 21: 404-12
|
|
|
|
|
|
27) Kikuchi A, Takeda A, Okamura N, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain. 2010; 133: 1772-8
|
|
|
|
|
|
28) Yabe I, Soma H, Takei A, et al. MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA. J Neurol Sci. 2006; 249: 115-21
|
|
|
|
|
|
29) Wenning GK, Ben Shlomo Y, Magalhaes M, et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994; 117 (Pt 4): 835-45
|
|
|
|
|
|
30) Jamora RD, Gupta A, Tan AK, et al. Clinical characteristics of patients with multiple system atrophy in Singapore. Ann Acad Med Singapore. 2005; 34: 553-7
|
|
|
|
|
|
31) Ozawa T, Takano H, Onodera O, et al. No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy. Neurosci Lett. 1999; 270: 110-2
|
|
|
|
|
|
32) Galvin JE, Lee VMTrojanowski JQ, Synucle-inopathies: clinical and pathological implications. Arch Neurol. 2001; 58: 186-90
|
|
|
|
|
|
33) Ozawa T, Healy DG, Abou-Sleiman PM, et al. The alpha-synuclein gene in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2006; 77: 464-7
|
|
|
|
|
|
34) Wenning GK, Wagner S, Daniel S, et al. Multiple system atrophy: sporadic or familial？ Lancet. 1993; 342: 681
|
|
|
|
|
|
35) Scholz SW, Houlden H, Schulte C, et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol. 2009; 65: 610-4
|
|
|
|
|
|
36) Yazawa I, Giasson BI, Sasaki R, et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron. 2005; 45: 847-59
|
|
|
|
|
|
37) Shults CW, Rockenstein E, Crews L, et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci. 2005; 25: 10689-99
|
|
|
|
|
|
38) Nakayama K, Suzuki YYazawa I, Microtubule depolymerization suppresses alpha-synuclein accumulation in a mouse model of multiple system atrophy. Am J Pathol. 2009; 174: 1471-80
|
|
|
|
|
|
39) Frison L, Pocock SJ, Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med. 1992; 11: 1685-704
|
|
|
|
|